Search research articles
Contact Us
Filters
Showing results (21-30 of 72) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors
Joan Albanell, Clara Montagut, Eileen T Jones, et al.
Journal of Medicinal Chemistry
|
February 22, 2023
Peptide-Platinum(IV) Conjugation Minimizes the Negative Impact of Current Anticancer Chemotherapy on Nonmalignant Cells
Jenniffer Linares, Monica Varese, Anna Sallent-Aragay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2002
Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon
Begoña Mellado, Maria Del Carmen Vela, Dolors Colomer, et al.
Cancer Chemotherapy and Pharmacology
|
March 12, 2016
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)
Russell Petty, Alan Anthoney, Jean-Philippe Metges, et al.
Cancer Research
|
June 19, 2008
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut, Sreenath V Sharma, Toshi Shioda, et al.
Science Translational Medicine
|
February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.
The Oncologist
|
August 19, 2018
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
Pilar García-Alfonso, Manuel Benavides, Esther Falcó, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2006
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity
Josep Domingo-Domenech, Cristina Oliva, Ana Rovira, et al.
Cancers
|
May 14, 2025
Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives
Valentino Martelli, Joana Vidal, Sílvia Salvans, et al.
British Journal of Cancer
|
November 24, 2018
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
Jesús García-Foncillas, Josep Tabernero, Elena Élez, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 72) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors
Joan Albanell, Clara Montagut, Eileen T Jones, et al.
Journal of Medicinal Chemistry
|
February 22, 2023
Peptide-Platinum(IV) Conjugation Minimizes the Negative Impact of Current Anticancer Chemotherapy on Nonmalignant Cells
Jenniffer Linares, Monica Varese, Anna Sallent-Aragay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2002
Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon
Begoña Mellado, Maria Del Carmen Vela, Dolors Colomer, et al.
Cancer Chemotherapy and Pharmacology
|
March 12, 2016
Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)
Russell Petty, Alan Anthoney, Jean-Philippe Metges, et al.
Cancer Research
|
June 19, 2008
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut, Sreenath V Sharma, Toshi Shioda, et al.
Science Translational Medicine
|
February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.
The Oncologist
|
August 19, 2018
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
Pilar García-Alfonso, Manuel Benavides, Esther Falcó, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2006
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity
Josep Domingo-Domenech, Cristina Oliva, Ana Rovira, et al.
Cancers
|
May 14, 2025
Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives
Valentino Martelli, Joana Vidal, Sílvia Salvans, et al.
British Journal of Cancer
|
November 24, 2018
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
Jesús García-Foncillas, Josep Tabernero, Elena Élez, et al.
Page
of 8